LPLUNC3 CRISPR/Cas9 KO Plasmid (h): sc-406344
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- LPLUNC3 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the LPLUNC3 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LPLUNC3 CRISPR/Cas9 KO Plasmid (h) | sc-406344 | 20 µg | $397.00 |
Overview
BPIFB3 (LPLUNC3) is a secreted member of the BPI fold–containing family enriched in mucosal epithelia, where it is thought to contribute to innate defense at airway and upper aerodigestive surfaces. Proteins in this family interact with microbial-associated lipids and can shape epithelial barrier homeostasis by influencing inflammatory signaling and antimicrobial responses. BPIFB3 expression is responsive to environmental and inflammatory cues and has been linked to regulation of epithelial differentiation programs and host–microbe interactions. Altered BPIFB3/LPLUNC3 levels have been reported across airway inflammatory states and epithelial-associated pathologies, supporting its utility as a marker and mechanistic node in mucosal biology research.
LPLUNC3 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the BPIFB3 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the BPIFB3 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the BPIFB3 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish LPLUNC3 protein expression.
This CRISPR knockout system enables efficient generation of BPIFB3-deficient cell models for investigation of LPLUNC3 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting BPIFB3 exon(s) critical for LPLUNC3 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple BPIFB3 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by LPLUNC3 CRISPR/Cas9 KO Plasmid (h) and LPLUNC3 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the BPIFB3 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by LPLUNC3 HDR Plasmid (h) and LPLUNC3 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by BPIFB3 homology arms to support homology-directed repair at defined BPIFB3 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.